Pfizer Drops Indiplon, Returns Rights To Neurocrine
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will continue to support the insomnia product for up to six months.
You may also be interested in...
Neurocrine Delays Indiplon Resubmission To Run Confirmatory Trial
Adding an insurance study to the NDA package means Neurocrine could finally see income from the insomnia aid in late 2008.
Neurocrine Delays Indiplon Resubmission To Run Confirmatory Trial
Adding an insurance study to the NDA package means Neurocrine could finally see income from the insomnia aid in late 2008.
Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year
Firm says formulary placement of the sleep aid will help mitigate Rx erosion following the launch of generic Ambien.